Archive for Urology News

ASCO GU: BP Reveals Hit or Miss for Targeted Tx

SAN FRANCISCO (MedPage Today) — Early response to preoperative targeted therapy for metastatic renal cell carcinoma may indicate efficacy, while treatment-induced hypertension may be another marker after surgery, according to studies reported here.

ASCO GU: Robotic Surgery Changes Some Prostate CA Treatment

SAN FRANCISCO (MedPage Today) — Robot-assisted surgery for prostate cancer may require alteration in radiation planning but doesn’t preclude sufficient lymph node sampling, according to results of two studies.

ACS Stats Find Gains in War on Cancer

Cancer is not quite the killer it was 20 years ago. The American Cancer Society found that “age-standardized” cancer deaths among men declined by 21% from 1990, while the rate among women declined by 12% from 1991 to 2006.

Americans Have Sex into Their 60s and Beyond (CME/CE, with audio)

Thirty-somethings can expect to enjoy at least another 30 years of sex, researchers have found.

ASCO GU: PSA Triggers Questioned in Active Prostate Surveillance (CME/CE)

SAN FRANCISCO (MedPage Today) — Most commonly-used methods to determine when to start prostate cancer treatment for men on watchful waiting have a high “false trigger” rate, researchers asserted.

ASCO GU: Higher-Priced Prostate Therapy Taking Over

SAN FRANCISCO (MedPage Today) — Expensive prostate cancer treatments are winning out over the old standards, driving up the cost of treatment before there’s clear evidence that they improve outcomes, researchers here asserted.

ASCO GU: Extensive Node Dissection Key for High-Risk Penile Cancer

SAN FRANCISCO (MedPage Today) — Thorough lymph node dissection improves survival in high-risk penile cancer but is vastly underused, researchers said here.

ASCO GU: Some Object to Cancer Society’s Prostate Screening Update

SAN FRANCISCO (MedPage Today) — Reactions to the American Cancer Society’s guideline update calling for shared decision making in prostate cancer screening have been mixed among urologists here at the Genitourinary Cancers Symposium, as a leading oncologist explains in this exclusive InFocus™ report.

ASCO GU: Assay Change Makes 3.0 the New 4.0 for PSA Cutoff

SAN FRANCISCO (MedPage Today) — A quiet switch in laboratory standards has artificially lowered prostate specific antigen (PSA) levels reported to physicians, confusing thresholds for biopsy and potentially leading to missed cancers.

ASCO GU: Prostate CA Prevention Affirmed for BPH Drug

SAN FRANCISCO (MedPage Today) — For men with benign prostatic hyperplasia (BPH), dutasteride (Avodart) both prevents prostate cancer and boosts the predictive power of prostate specific antigen (PSA), researchers affirmed.

ASCO GU: New Test Gets Positive Results for Prostate CA

SAN FRANCISCO Another novel urine test appears to improve detection of prostate cancer, particularly of aggressive tumors, researchers reported.

ASCO GU: Novel Retrovirus Mimics HIV Transmission

SAN FRANCISCO (MedPage Today) — A novel retrovirus implicated in prostate cancer appears to be transmitted much the way HIV is, researchers found.

PSA Debate Hashed Out in Congress

WASHINGTON (MedPage Today) — A day after the American Cancer Society (ACS) released updated prostate cancer screening guidelines, the group’s chief medical officer was before Congress urging the government to fund research into alternative methods for prostate cancer screening.

ASCO GU: Urine Screening Not Worth the Money in Bladder CA

SAN FRANCISCO (MedPage Today) — Adding urine tests to standard cytoscopy for surveillance after non-muscle invasive bladder cancer may increase cost without boosting detection, according to a prospective cost-effectiveness study.

ASCO GU: Novel Urine Test IDs Prostate Cancer

SAN FRANCISCO (MedPage Today) — An experimental urine test may pick up prostate cancers before biopsy in high-risk men, researchers found.

ASCO GU: Novel Agent Ups Survival in Refractory Prostate CA (CME/CE)

SAN FRANCISCO (MedPage Today) — The novel chemotherapy drug cabazitaxel substantially improves survival in hormone- and chemotherapy-refractory prostate cancer, making it the first treatment of any kind to do so.

ACS Pushes Shared Decisions for Prostate Screening (CME/CE)

Principles of shared decision-making should guide a man’s decision about screening for prostate cancer, according to updated guidelines from the American Cancer Society.

Outcomes Similar for Lap and Open Prostatectomy (CME/CE)

Laparoscopic and open prostatectomy have similar rates of comorbidity and similar requirements for additional therapy, according to a review of 5,923 cases of surgically treated prostate cancer.

Low Testosterone May Affect Cancer Survivors (CME/CE)

Male cancer survivors with low testosterone levels experience reduced energy and sexual function, and thus might benefit from hormone replacement therapy, a new study found.

AAPM: Nerve Growth Factor Antibody May Reduce Pain (CME/CE)

SAN ANTONIO (MedPage Today) — A humanized monoclonal antibody against nerve growth factor demonstrated efficacy in three chronic pain syndromes, according to a summary of small studies reported as an abstract here.

Stress of Prostate Cancer Diagnosis May Be Deadly (CME/CE, with audio)

Men have a slightly, but statistically significant, increased risk of dying from cardiovascular disease in the year after learning they have prostate cancer, researchers found.

ADT for Prostate Cancer Raises Heart Risks

Androgen deprivation therapy (ADT) for prostate cancer can exacerbate cardiac risk factors and may increase the risk of heart attack and cardiac death, according to an advisory issued by four medical organizations.

In Prostate CA, Sexual Decline After Radiation Has Limit (CME/CE)

Sexual function declines in the first two years after external beam radiation therapy for prostate cancer but stabilizes thereafter, according to data from a prospective cohort study.

Public-Private Divide Found in Prostate Cancer Treatment (CME/CE)

Treatment that men receive for prostate cancer may depend less on their condition and more on where they are treated, a new study found.

PET-CT Finds More Cancers than Standard Neurologic Screens (CME/CE, with video)

In patients who have neurologic symptoms indicative of cancer, whole-body positron emission tomography-computed tomography (PET-CT) may improve the detection rates when other screening test results are negative, researchers say.

Copyright @ 2001 and Beyond Fertility Portal: Fertility and Infertility Research News
Web Design By Dynamic Creator | Web Hosting by Trade Web Hosting